Back to Authors

Ighodaro, Eseosa T.

https://orcid.org/0000-0003-1186-1394

A5053085612 | I4405269449

Mayo Clinic

Wake Forest University Health Sciences

Citations 10

A Roadmap to Neurologic Health Equity

Neurology | February 11, 2026 | Volume: 106 | Issue: 5 | Pages: No page available

10.1212/wnl.0000000000214687 | PMID 41671520

A Neuropathologic Feature of Brain Aging: Multi-lumen Vascular Profiles (2750)

Neurology | December 7, 2023 | Volume: 96 | Issue: 15_supplement | Pages: No page available

10.1212/wnl.96.15_supplement.2750

A Case of Non-traumatic Subarachnoid Hemorrhage and Leptomeningeal Metastatic Melanoma (2738)

Neurology | December 7, 2023 | Volume: 96 | Issue: 15_supplement | Pages: No page available

10.1212/wnl.96.15_supplement.2738

Management of Chronic Subdural Hematoma in Patients Requiring Therapeutic Anticoagulation (2010)

Neurology | December 7, 2023 | Volume: 96 | Issue: 15_supplement | Pages: No page available

10.1212/wnl.96.15_supplement.2010

Enhancing inclusivity of older Black and African American adults in mental health research

Clinical Gerontologist | October 30, 2022 | Volume: 46 | Issue: 1 | Pages: 5-13

10.1080/07317115.2022.2133453 | PMID 36309844

Pearls & Oy-sters: Postpipeline Headache Phenomenon

Neurology | August 26, 2022 | Volume: 99 | Issue: 16 | Pages: 718-720

10.1212/wnl.0000000000201157 | PMID 36028323

Underreporting and Underrepresentation of Race and Ethnicity in Head and Neck Cancer Trials, 2010-2020

JAMA Otolaryngology–Head & Neck Surgery | June 2, 2022 | Volume: 148 | Issue: 7 | Pages: 662

10.1001/jamaoto.2022.1028 | PMID 35653143

Management of Chronic Subdural Hematoma in Patients Requiring Therapeutic Anticoagulation

The Neurologist | December 2, 2021 | Volume: 27 | Issue: 4 | Pages: 211-213

10.1097/nrl.0000000000000380 | PMID 34855670

Introduction: A common risk factor of chronic, nontraumatic subdural hematoma (SDH) is anticoagulation therapy. Anticoagulation is generally held in patients who develop SDH, but this can lead to thromboembolic events. While prior studies have reported the clinical outcomes of patients with anticoagulation-related SDH, there remains little evidence regarding ongoing anticoagulation treatment. Case Report: We report the management of 2 patients who developed anticoagulation-related SDH and underwent middle meningeal artery (MMA) embolization and successful reinitiation of anticoagulation therapy. In both patients, we conservatively managed anticoagulation with heparin and/or enoxaparin as a bridge to warfarin after MMA embolization. Follow-up computed tomography head revealed interval decrease of SDH and stable neurological status. Conclusions: These cases provide anecdotal evidence of a challenging clinical scenario where there is a necessary indication for therapeutic anticoagulation (ie, venous sinus thrombosis or atrial appendage thrombus) and comorbid SDH. Endovascular MMA embolization may be an effective adjunct therapy for clinical scenarios in patients with SDH and an urgent indication for anticoagulation. Longer follow-up, prospective series, and future randomized clinical trials are needed to objectively assess outcomes in this clinically challenging patient population.
Associations Between Plasma Ceramides and Cerebral Microbleeds or Lacunes

Arteriosclerosis, Thrombosis, and Vascular Biology | September 3, 2020 | Volume: 40 | Issue: 11 | Pages: 2785-2793

10.1161/atvbaha.120.314796 | PMID 32878474

Objective: High plasma ceramide levels and ratios are associated with poor outcomes in individuals with cardiovascular disease; less is known about their relation to cerebral small vessel disease. We examined whether high plasma ceramide levels or ratios were associated with cerebral microbleeds (CMBs) and lacunes and whether associations differ by sex. Approach and Results: We included 548 participants enrolled in the MCSA (Mayo Clinic Study of Aging) with concurrent plasma ceramide assays and magnetic resonance imaging. CMBs were quantified on T2* magnetic resonance imaging and lacunes on T2 fluid-attenuated inversion recovery magnetic resonance imaging. Fasting plasma ceramides were assayed using liquid chromatography-electrospray ionization tandem mass spectrometry. We used logistic regression models adjusting for age, sex, hypertension, and diabetes mellitus to examine the relationship between ceramides and presence of a lacune; hurdle models were used for presence and number of CMBs. Each SD increase in the log ceramide C16:0/24:0 ratio was associated with greater odds of a CMB (odds ratio, 1.28 [95% CI, 1.01–1.64]). There was an interaction between sex and the ceramide C16:0/24:0 ratio ( P =0.049). The association between this ratio and presence of a CMB was stronger for women (odds ratio, 1.87 [95% CI, 1.20–3.00]) than men (odds ratio, 1.09 [95% CI, 0.80–1.46]). Several ceramides and all ceramide ratios were associated with number of CMBs. We did not find associations between plasma ceramides and lacunes. Conclusions: In a population-based sample, the plasma ceramide C16:0/24:0 ratio was associated with CMBs and was stronger for women. Plasma ceramides are differentially associated with cerebral small vessel pathologies.
Insights From African American Older Adults on Brain Health Research Engagement: “Need to See the Need”

Journal of Applied Gerontology | February 4, 2020 | Volume: 40 | Issue: 2 | Pages: 201-208

10.1177/0733464820902002 | PMID 32013658

African Americans (AAs) have an elevated risk of developing dementia, yet are underrepresented in clinical research. This project uses a community-engaged photovoice approach to add to existing understanding of barriers and facilitators to AA participation in Alzheimer’s disease research and identify strategies to enhance engagement. Three AA research advocates served as community facilitators to identify and guide groups of AA adults through an eight to nine session photovoice project. Group sessions involved discussions and sharing of images pertaining to various prompts in the area of brain health and research participation. Sessions were audiotaped and transcribed verbatim. Participants identified three categories of barriers to AA research participation: (a) Mistrust, (b) avoidance and fear of acknowledging problems, and (c) seeing the risks of research but not the need. Participants shared suggestions and approaches for ameliorating each of these barriers. This process revealed unique insights into barriers and opportunities for increasing AA engagement in aging and dementia research.